Piramal Pharma Targets $2 Bn Revenue By 2030 | Focus On Organic Growth & Innovation| Nandini Piramal

Piramal Pharma aims to achieve a revenue of $2 billion by 2030. Their goal is to become one of the top 10 players in their target markets by focusing on key metrics and investment opportunities. The company plans to enhance margins and capitalize on synergies in the cdmo segment through increased volume growth. Their strategy primarily revolves around organic growth and the development of innovative products. This aligns with Piramal Pharma's global business perspective, which includes potential opportunities arising from the U.S. Biosecure Act. Additionally, they have plans for capital expenditure utilization and expansion. New partnerships are also in the pipeline.
#piramalpharma #healthcare #pharmasector #pharmastocks #usbiosecureact #piramalpharmashare #investment #etnow #businessnews #topnews
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► goo.gl/SEjvK3
Subscribe Now To Our Network Channels :-
Times Now : goo.gl/U9ibPb
The NewsHour Debate : goo.gl/LfNgFF
To Stay Updated Download the Times Now App :-
Android Google Play : goo.gl/zJhWjC
Apple App Store : goo.gl/d7QBQZ
Social Media Links :-
Twitter - goo.gl/hA0vDt
Facebook - goo.gl/5Lr4mC
G+ - goo.gl/hYxrmj
Website - www.etnownews.com

[@Nomad_Wanderer]

San ambani ji ki kirpa hai.